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Introduction:  In the  UK,  primary  varicella  is usually  a mild  infection  in  children,  but can  cause  seri-
ous  illness  in susceptible  pregnant  women  and  adults.  The  UK  Joint  Committee  on  Vaccination  and
Immunisation  is  considering  an  adolescent  varicella  vaccination  programme.  Cost-effectiveness  depends
upon identifying  susceptibles  and  minimising  vaccine  wastage,  and  chickenpox  history  is  one  method  to
screen  for  eligibility.  To  inform  this  approach,  we  estimated  the  proportion  of adolescents  with  varicella
antibodies  by reported  chickenpox  history.
Methods:  Recruitment  occurred  through  secondary  schools  in England  from  February  to  September  2012.
Parents were  asked  about  their  child’s  history  of  chickenpox,  explicitly  setting  the  context  in terms  of
the  implications  for  vaccination.  247  adolescents,  whose  parents  reported  positive  (120),  negative  (77)  or
uncertain  (50)  chickenpox  history  provided  oral  ﬂuid  for varicella  zoster  virus-speciﬁc  immunoglobulin-G
(VZV-IgG)  testing.
Results: 109  (90.8%  [85.6–96.0%])  adolescents  with  a  positive  chickenpox  history,  52 (67.5%  [57.0–78.1%])
with  a negative  history  and  42  (84.0%  [73.7–94.3%])  with  an  uncertain  history  had  VZV-IgG  suggest-
ing  prior  infection.  Combining  negative  and  uncertain  histories,  74%  had  VZV-IgG  (best-case).  When
discounting  low  total-IgG  samples  and  counting  equivocals  as positive  (worst-case),  84% had  VZV-IgG.
We  also  modelled  outcomes  by varying  the  negative  predictive  value  (NPV)  for the  antibody  assay,  and
found  74–87%  under  the  best-case  and  84–92%  under  the worst-case  scenario  would  receive  vaccine
unnecessarily  as  NPV  falls  to  50%.
Conclusion:  Reported  chickenpox  history  discriminates  between  varicella  immunity  and susceptibility  in
adolescents,  but  signiﬁcant  vaccine  wastage  would  occur  if this  approach  alone  were  used  to  determine
vaccine  eligibility.  A small  but important  proportion  of  those  with  positive  chickenpox  history  would
remain  susceptible.  These  data  are needed  to  determine  whether  reported  history,  with  or  without  oral
ﬂuid  testing  in  those  with  negative  and  uncertain  history,  is  sufﬁciently  discriminatory  to  underpin  a
cost-effective  adolescent  varic
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1. Introduction
Primary varicella infection (chickenpox) is an acute illness
Open access under CC BY license.caused by varicella-zoster virus (VZV), which is characterised by
a generalised vesicular rash, fever and malaise. [1] In the UK, most
chickenpox occurs in children under 10 years old and is mild. Sero-
prevalence data suggest 80% of 11-year-olds in England and Wales
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ave previously been exposed to varicella infection. [2] Serious
llness mainly occurs in immunocompromised individuals and the
emaining susceptible adults, which is of particular concern in
regnancy, and may  lead to maternal complications (e.g. varicella
neumonia) and severe foetal consequences (e.g. congenital vari-
ella syndrome). When VZV reactivates from dorsal root ganglia in
ater life, this causes a painful dermatomal rash known as herpes
oster or shingles.
Universal varicella immunisation has not been introduced in
he UK, in part due to concerns that this may  shift the burden of
rimary disease to susceptible adults, who are at higher risk of com-
lications, [3–5] and increase shingles reactivations, due to reduced
atural boosting in those previously exposed [4,5]. A recent review
y the Joint Committee on Vaccination and Immunisation (JCVI)
oncluded that a two-dose childhood varicella vaccination sched-
le was not cost-effective, but JCVI did recommend a single-dose
erpes zoster vaccine for adults aged 70–79 [6].
To prevent severe primary infections among adults, alternative
pproaches to routine childhood varicella vaccination are being
onsidered in the UK [7]. In particular, the introduction of a selective
dolescent varicella vaccination programme may  be cost-effective
5]. Given that most adolescents will have acquired natural immu-
ity, the cost-effectiveness of this approach will largely depend
pon accurate pre-immunisation identiﬁcation of susceptibles to
inimise vaccine wastage in those already immune. Two  screening
ethods are available: reported chickenpox history, or laboratory
esting for VZV-speciﬁc immunoglobulin G (IgG) antibody, which
s signiﬁcantly more expensive, more time consuming and likely to
nvolve higher dropout rates.
Understanding the validity of reported chickenpox history in
he target group is essential to inform this decision, and to model
he impact and cost-effectiveness of the overall approach. Oral ﬂuid
gingivocrevicular ﬂuid) is simple and non-invasive to collect, and
ith appropriately sensitive assays can be used for the detection of
iral antibodies for seroprevlance studies [8]. This study estimates
he proportions of adolescents already immune to VZV, by reported
hickenpox history, using detection of VZV-speciﬁc antibodies in
ral ﬂuid as a serological correlate suggesting previous infection.
. Methods
Recruitment occurred during February to September 2012. The
tudy aimed to recruit a group broadly representative of the British
eneral population, where approximately 15% of adolescents are of
on-white ethnicity, [9] because differences in the predictive value
f chickenpox history by ethnicity have been reported. [10,11] Ado-
escents were therefore recruited through two secondary schools
n South London to increase the number of non-white participants,
nd two other regions of England (Hertfordshire and Gloucester-
hire). Participating schools provided all students aged 11–15 with
tudy information packs to take home to their parents. Individuals
ith any serious health condition causing immune dysfunction,
ho would be ineligible to receive a live vaccine, and those who
ad previously received a varicella vaccine were excluded.
Study packs asked parents to return a short questionnaire by
ost, including their child’s ethnicity and the following question
bout chickenpox history: “Most children will have had chicken-
ox by the time they are 10 years old. Chickenpox infection provides
ong-term protection against future infection and there is no need for
accination if someone has already had chickenpox. We  want you to
hink about your child’s history of chickenpox in this context. Has your
hild had chickenpox?” Answers were: (1) “Yes (If yes, your child
oes not need chickenpox vaccine)”, (2) “No” or (3) “I don’t know”. To
ncrease the number of negative and uncertain responses towards
he end of the study, after receiving over 500 positive responses, (2014) 1213–1217
the question was  altered to, “Has your child had chickenpox? (If you
answer yes, we do NOT need you to complete or return this form as we
have now received enough replies from this group)”.
Parents who  returned the questionnaire were sent a consent
form and a kit to collect oral ﬂuid, with clear instructions on how to
obtain a sample from their child, which they were asked to return to
the Health Protection Agency (HPA). Approximately 7000 introduc-
tory letters were distributed by schools; 550 questionnaires were
returned with a positive history of chickenpox, 84 with a negative
history, and 56 with an uncertain history, and 1 was incomplete. We
posted 268 oral ﬂuid kits, including 128 to respondents with a pos-
itive history of chickenpox and all those with negative or uncertain
histories.
Families were informed at the outset in the initial study informa-
tion pack that, as a token of appreciation, a voucher for £10 would
be sent to them once a sample was  received in the laboratory. Chil-
dren found to be susceptible to varicella were offered two doses of
varicella vaccine without charge.
2.1. Laboratory procedures
Oral ﬂuid samples and consent forms were received by the
HPA Virus Reference Department, MS-Colindale, and processed to
extract VZV-IgG using standard methods and diluents. Oral ﬂuid
samples were stored at −30 ◦C prior to batch testing. For semi-
quantitative determination of IgG antibodies to VZV, the in-house
VZV-IgG time resolved ﬂuorescence immunoassay, (TRFIA), [12]
was modiﬁed for testing oral ﬂuid. Testing of paired serum and oral
ﬂuid samples, had previously established that measurements above
a cut-off of 0.35 mIU/mL should be considered positive, below a cut-
off of 0.25 mIU/mL as negative, with an equivocal range between
0.25 and 0.35 mIU/mL. [HPA unpublished data] Samples testing
negative or equivocal were also tested for total IgG to determine
whether the sample had been taken appropriately and contained
sufﬁcient total IgG, using a cut-off of greater than 2.5 mg/L.
2.2. Data analysis
Data were analysed using Stata v12 (Statcorp, TX, US). For each
chickenpox history group, we aimed for a sample size of 100, to esti-
mate with reasonable precision the proportion with VZV-IgG (95%
conﬁdence interval within ±10%). The study was not designed or
powered to detect differences by ethnicity. Exact 95% conﬁdence
intervals for proportions were calculated and proportions com-
pared according to history using two-sided Fisher’s exact tests. We
also undertook a sensitivity analysis to investigate the impact of
using the oral ﬂuid assay in populations with different VZV-IgG
prevalence by modelling the effect of different values for the neg-
ative predictive value (NPV) of the assay.
3. Results
120 oral ﬂuid samples were received from respondents with a
positive history of chickenpox, 77 with a negative history and 50
with an uncertain history. The average age of respondents was  13
years, and 85% were white, 6% mixed ethnicity, 6% Asian, 3% Black,
and 1% Chinese. The groups with different history responses were
not signiﬁcantly different with respect to age or ethnicity (data not
shown).
Overall, 109 (90.8% [95% CI 85.6–96.0%]) with a positive his-
tory of chickenpox, 52 (67.5% [57.0–78.1%]) with a negative history
and 42 (84.0% [73.7–94.3%]) with an uncertain history had VZV-
IgG antibodies indicating previous varicella infection (Table 1). 16
oral ﬂuid samples were found to have insufﬁcient total IgG for
reliable detection of speciﬁc VZV-IgG, including 13 (81%) from
respondents with a negative or uncertain history, suggesting these
N. Field et al. / Vaccine 32 (2014) 1213–1217 1215
Table  1
Reported history of chickenpox and VZV-IgG results.
VZV IgG Result Total
Positive Negative Equivocal Insufﬁcient
n  (%) n (%) n (%) n (%) n
Chickenpox history
Positive 109 (90.8%) 7 (5.8%) 1 (0.8%) 3 (2.5%) 120
Negative 52 (67.5%) 13 (16.9%) 2 (2.6%) 10 (13.0%) 77
Uncertain 42 (84.0%) 5 (10.0%) 0 (0.0%) 3 (6.0%) 50
Total  203 (82.2%) 25 (10.1%) 3 (1.2%) 16 (6.5%) 247
Table 2
Best-case scenario: validity of chickenpox history, grouping together negative, equivocal and insufﬁcient IgG.
VZV IgG Result Total
Positive Negative, equivocal or insufﬁcient
n % [95% CI] n % [95% CI] n
Chickenpox history
Positive 109 90.8% [85.6–96.0%] 11 9.1% [4.0–14.4%] 120
Negative 52 67.5% [57.0–78.1%] 25 32.5% [21.2–43.0%] 77
Uncertain 42 84.0% [73.7–94.3%] 8 16.0% [5.7–26.3%] 50
Negative or uncertain 94 74.0% [66.3–81.7%] 33 26.0% [18.3–33.7%] 127
p-Values for comparison of proportions were calculated as follows: positive vs. negative: p < 0.001; positive vs. negative or uncertain: p < 0.001; positive vs. uncertain:
p  = 0.284; negative vs. uncertain: p = 0.041.
Table 3
Worst-case scenario: validity of chickenpox history, discounting insufﬁcient IgG and counting equivocal as positive.
VZV IgG Result Total
Positive or equivocal Negative
n % [95% CI] n % [95% CI] n
Chickenpox history
Positive 110 94.0% [89.7–98.4%] 7 6.0% [1.6–10.3%] 117
Negative 54 80.6% [71.0–90.2%] 13 19.4% [9.8–29.0%] 67
Uncertain 42 89.4% [80.4–98.3%] 5 10.6% [1.7–20.0%] 47
Negative or uncertain 96 84.2% [77.5–91.0%] 18 15.8% [9.0–22.5%] 114
p egative: p = 0.007; positive vs. negative or uncertain: p = 0.020; positive vs. uncertain:
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ay  be true negatives. To assess the best-case scenario, our ini-
ial analysis therefore grouped together negative, equivocal, and
nsufﬁcient oral ﬂuid results (Table 2). Under these conditions, 11
9.1% [4.0–14.4%]) with a positive history, 25 (32.5% [21.2–43.0%])
ith a negative history and 8 (16.0% [5.7–26.3%]) with an uncer-
ain history had no evidence of previous varicella infection. An
dolescent varicella immunisation programme would offer the vac-
ine to those with either a negative or uncertain history, of whom
4 (74.0% [66.3–81.7%]) were positive for VZV-IgG and 33 (26.0%
18.3–33.7%]) were negative.
To assess the worst-case scenario, our second analysis dis-
ounted samples with insufﬁcient IgG and assumed equivocal
esults were positive (Table 3). Under these conditions, 96 (84.2%
77.5–91.0%]) with a negative or uncertain history of chickenpox
ad antibodies indicating previous varicella infection.
Using paired serum and oral ﬂuid samples, the assay used in
his study was previously shown to have a sensitivity of 96.3% and
peciﬁcity of 90.9%. [HPA unpublished data] In populations with
 high seroprevalence of VZV-IgG, the positive predictive value
PPV) of this assay will approach 100%, but NPV may  be lower. To
xplore this, we assumed the PPV to be 100% and varied the NPV
etween 50% and 100%. Using the study data as described above,
ig. 1 shows the impact on the expected proportion of respondents
ith a negative or uncertain chickenpox history testing positive
or VZV-IgG (i.e. the proportion of vaccine-eligible individuals who
ight receive vaccine unnecessarily). Under the best-case scenario,Fig. 1. The effect of varying the negative predictive value (NPV) of the oral ﬂuid assay
on  the proportion of individuals with negative or uncertain chickenpox history and
evidence of previous varicella infection.
this proportion increased from 74% to 87% and under the worst-case
scenario from 84% to 92% as NPV falls to 50%.4. Discussion
Adolescent varicella vaccination is being considered in the UK
with the aim of preventing serious adult disease and to avoid
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nfection in pregnancy in those susceptible. Previous reviews have
ound antenatal screening for varicella, and childhood vaccination
ot to be cost-effective [6,13]. Cost-effectiveness of an adolescent
aricella vaccination programme in the UK is likely to depend on
he proportion of vaccine doses given unnecessarily to individuals
ith prior natural immunity. We  therefore assessed the validity
f reported chickenpox history to determine vaccine eligibility, by
sking parents about their child’s history of chickenpox, explicitly
etting the context in terms of the implications for vaccination. We
hen tested the adolescents for varicella antibodies to determine
revious exposure. At best, 68% of those with negative history and
4% of those with a negative or uncertain history might receive
accine unnecessarily. At worst, vaccine would be wasted in 81%
f those with negative history and 84% with negative or uncertain
istory. These data provide a useful range of estimates to model
he likely cost-effectiveness of preventing adult varicella disease
y vaccinating adolescents.
We also provide estimates for the proportion of adolescents
ith a positive history of chickenpox and no evidence of previous
aricella infection (6–9%), who would remain susceptible if disease
istory was used to determine vaccine eligibility. This group may
omprise a substantial proportion of all susceptibles in the pop-
lation because the majority of the population is likely to have a
ositive history. These data will inform modelling estimates of the
emaining disease burden following implementation of a vaccine
rogramme based on chickenpox history. Cost-effectiveness analy-
is would also take account of immunocompromised susceptibles,
ho would not be eligible for a live attenuated vaccine but would
e at greater risk of severe disease.
Other countries have adopted adolescent varicella immun-
sation strategies, including Australia, where a school-based
mmunisation programme targeting adolescents aged 10–13 years
ith no previous history of chickenpox or varicella vaccination
as been in place since 2006 [14], and European countries such
s Austria, Cyprus, Germany, Greece, Italy, Spain and Turkey [15].
ome previous studies have investigated the validity of chicken-
ox history in adolescents, for example, in Greece [16], Switzerland
17], Turkey [18], and the American military [19]. Other studies
ave investigated other groups at other ages, for example, health
are workers [11,20,21], hospital patients, [22,23] pregnant women
24–26], refugees [27], and army recruits [28,29]. Many studies are
et in other countries, where the natural history and prevalence of
aricella infection differs, and sometimes with different objectives,
uch as to decide the risk in pregnant women following exposure
o chickenpox infection [30], where the tolerance for error is much
ower. As such, there is a broad range of published estimates for
he proportion of individuals with negative or uncertain chicken-
ox history and previous varicella infection [32,33], and in some
ases this is extremely low (11%) [31], which makes generalisa-
ion difﬁcult. Our study is the ﬁrst, to the best of our knowledge,
o frame the history question about previous chickenpox disease
peciﬁcally within the context of the implications for vaccination
f adolescents.
To maximise the use of our data in other settings, where the
revalence of varicella (and therefore NPV) may  differ, we  present
ll assay data from the study (Table 1), including equivocal results
nd samples with low total IgG, and model the impact of varying
he assay NPV between 50% and 100% (Fig. 1). The oral ﬂuid assay,
sing a modiﬁed TRFIA to detect speciﬁc VZV-IgG antibody, was
hosen because it avoids any invasive procedure to collect blood
nd is more likely to be acceptable to parents and adolescents, thus
mproving study response rates.A recently proposed change to the UK adolescent vaccination
rogramme would mean that a group C meningococcal booster
accine may  be offered with the Td/IPV (tetanus, diphtheria, polio)
ooster to those aged 13–14 [34], and an adolescent varicella (2014) 1213–1217
vaccination programme could be given at the same time. The
average age of participants in this study was 13 years, and the
study population intentionally reﬂects ethnic diversity in the UK
adolescent general population through the inclusion of two schools
in South London to increase the number of non-white respondents.
Among all study respondents providing an oral ﬂuid sample, 82%
tested positive for VZV-IgG, which reﬂects the likely prevalence
in the UK for this age group. [2] Our study, however, did not
aim to provide population prevalence estimates for the different
chickenpox history responses because it was  not possible to assess
how accurately respondents reﬂect the population. For example,
parents of adolescents with negative or uncertain histories may
have been more likely to participate given the provision of free
vaccine to those without VZV-IgG antibodies. The proportion with
different histories may  also have been affected by changing the
question about chickenpox history at the end of the study to boost
the number of negative and uncertain responses, and the small
token of appreciation offered. Finally, it is difﬁcult to foresee how
parents’ answers might be inﬂuenced by the prospect of their child
actually receiving a vaccine in the context of a national adolescent
vaccination programme.
5. Conclusion
We  show that asking parents to report their child’s chickenpox
history can signiﬁcantly discriminate between adolescents who are
immune and susceptible to varicella infection. These data will be
used to determine by modelling whether reported history, with
or without oral ﬂuid testing in those with negative or uncertain
history, is sufﬁciently discriminatory to underpin a cost-effective
varicella vaccination programme that will protect susceptibles
against chickenpox in the UK.
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